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Short-term survival beneﬁ ts of endovascular aneurysm 
repair (EVAR) versus open repair of elective abdominal 
aortic aneurysms have been shown in randomised trials, 
but this early survival beneﬁ t is lost within a few years.1–3 
The long-term survival beneﬁ t of EVAR remains unclear.4 
The randomised controlled EVAR trial 1 was initiated 
in 1999, and the EVAR trial participants and authors are 
to be congratulated for their persistence to obtain these 
long-term data in this aneurysm population suitable 
for both open repair and EVAR.1 In Rajesh Patel and 
colleagues’ EVAR trial 15 reported in The Lancet, over a 
mean of 12·7 years’ follow-up (max 15·8 years), they show 
no signiﬁ cant diﬀ erence between the randomly assigned 
groups in total mortality (9·3 deaths per 100 person-years 
in the EVAR group vs 8·9 deaths per 100 person-years in 
the open-repair group) or aneurysm-related mortality 
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esomeprazole or rabeprazole at high doses.11 Additionally, 
amoxicillin three times a day could have been prescribed 
as it was proposed in east Asia, potentially increasing the 
eradication frequency.12 Furthermore, these results might 
not be generalisable to other populations; Asians tend 
to be smaller and lighter than individuals of other ethnic 
origins and therefore the smaller volume of antibiotic 
distribution might have positively aﬀ ected the outcome 
of treatments.
With regard to adverse events, beyond the usual 
symptoms, there was a consequence of treatment not 
yet assessed—ie, the eﬀ ect on gut microbiota with long-
term eﬀ ects on the patients that might be diﬀ erent 
according to the compounds used. Also the discrepancy 
(up to 5%) between the results of phenotypic and 
genotypic resistance for both clarithromycin and 
ﬂ uoroquinolones raises a question about the most 
accurate method for susceptibility testing.
Overall, this study shows that some empirical 
treatments, especially bismuth quadruple therapy, can 
lead to excellent eradication frequencies, thanks to 
bismuth salts and tetracycline for which no resistance 
is usually found and can therefore be an alternative to 
the tailored treatments after antimicrobial susceptibility 
testing. If concomitant therapy, the other eﬀ ective 
regimen in the study, is used, the recommended 
treatment duration should be 14 days unless 10 days are 
proven eﬀ ective locally.11
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(1·1 deaths per 100 person-years in the EVAR group 
vs 0·9 deaths per 100 person-years in the open-repair 
group). An early and signiﬁ cant survival beneﬁ t was noted 
in the EVAR group at 6 months after randomisation 
(adjusted hazard ratios 0·61, 95% CI 0·37–1·02 for total 
mortality; and 0·47, 0·23–0·93, p=0·031 for aneurysm-
related mortality), and only after 8 years did open repair 
have a signiﬁ cantly lower mortality (1·25, 1·00–1·56, 
p=0·05 for total mortality; and 5·82, 1·64–20·65, p=0·006 
for aneurysm-related mortality). The increased aneurysm-
related mortality beyond 8 years was mainly attributable 
to secondary aneurysm sac rupture post-EVAR. Overall, 
aneurysm re-intervention rates were higher in the 
EVAR than in the open-repair group (4·1 and 1·7 per 
100 person-years; p<0·0001) with most re-interventions 
taking place within 4 years of the initial treatment.5
In this trial, patients were treated more than 
12 years ago and, fortunately, medical and endovascular 
management have since progressed. Case selection, 
device choice,6 and planning with technical skills by use of 
simulation,7 imaging modalities with decreased radiation, 
best practices in medical treatment, and surveillance 
programmes in centralised aortic units have all improved 
the overall management of aortic aneurysmal disease.8 
Although the EVAR trial 1 will always be a landmark trial, 
the long-term ﬁ ndings with only 57% of patients being 
alive at the end of follow-up should be interpreted with 
caution because of the following limitations. 
The data collection from 10–15 years risks bias since 
it was done both retrospectively and prospectively, and 
relies on data from NHS records for procedures at the 
time of patient discharge (Hospital Episode Statistics) 
and trial-based data. The beneﬁ t was that patients lost to 
follow-up were retrieved and that re-interventions after 
open repair, such as incisional hernia repair, not collected 
before 2009, could be included in a retrospective 
manner. Follow-up for mortality (the primary outcome) 
was unchanged between 1999 and 2015.
In 1999, the mean age at randomisation for the 
EVAR trial 1 was 74 years, indicating that patients 
were a high-risk group for malignancy based on age 
rather than radiation exposure. The diﬀ erence in total 
malignancy deaths at 15 years is small (126 in the EVAR 
group vs 123 in the open-repair group) and in fact more 
malignancy deaths were noted in the open-repair group 
at time intervals 6 months to 4 years and at 4–8 years. 
Appropriate investigation and robust data are needed 
and any insinuation that EVAR predisposes to or increases 
the risk of cancer might be dangerously misleading. 
The long-term surveillance after aneurysm repair in 
the UK trial, a country known for its evidence-based 
medicine, was astonishingly low despite reports warning 
the endovascular community about the importance of 
lifelong follow-up.9
Unfortunately, imaging data have not yet been 
included to explain why aneurysms excluded with 
second and third generation devices still rupture during 
long-term follow-up. Was this aneurysm growth or 
rupture caused by true device failures10 (eg, fractures, 
migration, endoleak type I or III), or was the initial stent 
graft not deployed within 3 mm of the lowest renal 
artery? Was surveillance continued for long enough 
(median CT surveillance six scans [IQR 3–8] in EVAR 
group vs three scans [1–6] in open-repair group5) 
and were serious and life-threatening complications 
managed appropriately by secondary interventions (such 
as by relining, coiling, proximal fenestrated cuﬀ ) to save 
the patient’s life?10 Local investigators in this trial by Patel 
and colleagues5 were at liberty to treat patients to their 
best knowledge, but some complications that are now 
known to cause aneurysm rupture were not treated.11 
EVAR has gained enormous popularity worldwide 
with a lower initial operative mortality than open repair. 
Secondary ruptures after EVAR account for the long-term 
increase in aneurysm-related mortality. These ﬁ ndings, 
conﬁ rmed by 15 years of follow-up data from the EVAR 1 
trial,5 should alert physicians managing abdominal aortic 
aneurysms and might have implications for case 
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Surgical innovation strives to address the perceived 
shortcomings and potential pitfalls associated with 
traditional therapeutic techniques. New devices are often 
recommended to patients on the basis of incomplete 
clinical datasets that highlight speciﬁ c short-term gains 
over standard treatment but may not conﬁ rm long-
term beneﬁ t. Enthusiasm for new technology in surgery 
should be balanced by the requirement to undertake 
objective, high-quality studies to establish the overall 
clinical and economic eﬀ ect of surgical therapies.1
In The Lancet, Angus Watson and colleagues present 
eTHoS,2 a randomised, non-blinded, multicentre, phase 3 
study assessing clinical outcomes and cost-eﬀ ectiveness 
for treatment of moderate or severe haemorrhoids 
using novel stapled haemorrhoidopexy versus the long-
established traditional excisional haemorrhoidectomy.2 
These outcomes are of importance as each year millions 
of people are aﬀ ected by haemorrhoids worldwide;3 
the UK National Health Service carries out in excess of 
20 000 haemorrhoidal treatments.4
Traditional haemorrhoidectomy excises symptomatic 
tissue from the anal canal leaving wounds that usually 
take 6 weeks to heal.5 Surgeons often contend that 
traditional haemorrhoidectomy is a good treatment for 
haemorrhoids, the axiom of “6 weeks’ pain for 5 years’ 
gain” has long been touted, although surprisingly little 
high-quality evidence exists to support this position.6 
Patients experience short-term discomfort after traditional 
haemorrhoidectomy until their anal canal wounds heal, 
and, if severe, this pain might give rise to additional 
problems such as a fear of evacuation, constipation, and 
an inability to pass urine requiring catheterisation.
Stapled haemorrhoidopexy was speciﬁ cally developed 
to tackle the problem of early pain after traditional 
haemorrhoidectomy.7 A ring of tissue is excised from the 
relatively insensate, viscerally innervated upper anal canal, 
with the cut edges simultaneously brought together and 
ﬁ xed by a circle of staples. Traction draws the prolapsing 
haemorrhoids into the anal canal where they remain ﬁ xed 
(pexy). Stapling might also interrupt the submucosal 
blood ﬂ ow to haemorrhoids, thereby reducing symptoms 
of bleeding. Initial experience reinforced the view that 
stapled haemorrhoidopexy was less painful for patients 
than traditional haemorrhoidectomy, however, severe 
eTHoS piles pressure on haemorrhoidopexy
selection, patients’ treatment choices, and continuous 
surveillance after EVAR. These results also show that 
long-term follow-up of surgical innovations is crucial.12
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